Search clinical trials for: CC-90001

Total 887 results

Novo Nordisk A/S

Recruiting

First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases

Healthy Volunteers

United Kingdom
Sarepta Therapeutics, Inc.
Hoffmann-La Roche

Enrolling by invitation

A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study (EXPEDITION)

Duchenne Muscular Dystrophy

United States
Sarepta Therapeutics, Inc.

Completed

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana

Lassa Fever

Ghana
Johannes Kepler University of Linz

Recruiting

Diagnostic Possibilities in Ophthalmological Diseases Using Swept Source Optical Coherence Tomography

Macular Degeneration | Diabetic Retinopathy | Retinal Disease

Austria
Sara V. Latorre
Instituto de Salud Carlos III; Institut d'Investigacions Biomèdiques August...

Active, not recruiting

Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy (CART19-BE-02)

Acute Lymphoid Leukemia

Spain
Sarepta Therapeutics, Inc.

Completed

A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)

Muscular Dystrophy, Duchenne

United States
Celgene

Recruiting

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid

United States, France, Canada
Celgene

Active, not recruiting

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

Spain, Canada, United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

France, Spain
Celgene

Completed

Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene

Completed

Japanese Pharmacokinetic Bridging Study for CC-93538

Healthy Volunteers

United States
Celgene

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

Healthy Volunteer

United States
Celgene

Terminated

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Celgene

Completed

Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study

Clinical Pharmacology, Healthy Male Volunteer Study

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Engineered Immune Effectors Against Cervical Cancer

Cervical Cancer

China
Universitair Ziekenhuis Brussel

Unknown

Single-center Prospective Cumulus Cell Test Study in rFSH Patients

Infertility

Belgium
Universitair Ziekenhuis Brussel

Unknown

Single-center Prospective Cumulus Cell Test Study (CC-Test)

Pregnancy

Belgium
National Cancer Institute (NCI)

Completed

CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas

Brain and Central Nervous System Tumors

United States
Boston Medical Center

Completed

Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia

United States
Celgene Corporation

Completed

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

Glioblastoma | Malignant Gliomas

United States
Celgene

Withdrawn

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Sarcoidosis
Celgene

Completed

A Study of CC-90011 and Comparators in Participants With Prostate Cancer

Prostatic Neoplasms

United States
Celgene

Active, not recruiting

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

France, Canada, United States, Spain
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male Participants

Healthy Volunteers

United States
Jean Edward

Completed

Coverage and Cost-of-Care (CC) Links- Financial Navigation Program (CC Links)

Financial Stress | Survivorship | Hematologic Cancer

United States
Benjamin Rose Institute on Aging

Withdrawn

SHARE for Persons With Chronic Conditions and Their Family Caregivers (SHARE-CC)

Family Caregivers | Chronic Health Conditions

United States
Celgene

Completed

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

Healthy Volunteers | Hepatic Impairment

United States
Celgene

Completed

Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Sun Yat-sen University
Ministry of Health, China; Xidian University

Completed

Validation of the Utility of Rare Disease Intelligence Platform

Cataract | Artificial Intelligence

China
Inovio Pharmaceuticals
Coalition for Epidemic Preparedness Innovations

Completed

Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers

Lassa Fever

United States
Kaiser Clinic and Hospital

Completed

Optimization and Follow-up of the Consecutive Use of Two Intragastric Balloons in the Treatment of Obesity

Obesity | Metabolic Syndrome

Brazil
VA Office of Research and Development

Not yet recruiting

Home-based Conservative Care Model for Advanced Kidney Disease

Chronic Kidney Diseases

United States
Celgene

Completed

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

Japan
Nobel Biocare

Completed

A 5-year Clinical Evaluation Study on NobelReplace Conical Connection Implants

Healthy | Implant
Celgene

Completed

Radiolabeled Study of CC-122 in Healthy Subjects

Healthy Volunteers

United States
Universitair Ziekenhuis Brussel

Unknown

Multicenter Prospective Cumulus Cell Test Study (MC_CC-Test)

Pregnancy

Belgium
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

Renal Insufficiency

United States
Celgene

Completed

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene Corporation

Terminated

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Myeloid Leukemia

United States
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
Celgene

Completed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

Healthy Volunteers

United States
Celgene

Terminated

A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis

Psoriasis | Healthy Volunteers

Germany
Celgene

No longer available

Expanded Access for Marizomib

Solid Tumor

United States
Celgene

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of CC-99677 in Healthy Adult Subjects

Healthy Volunteer

United Kingdom
Celgene

Terminated

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

Discoid Lupus

United States
University of Washington
Patient-Centered Outcomes Research Institute

Completed

Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study (MS-CARE)

Depression | Pain | Multiple Sclerosis

United States
Sarepta Therapeutics, Inc.
Hoffmann-La Roche

Enrolling by invitation

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) (ENDEAVOR)

Muscular Dystrophy, Duchenne

United States
PharmAbcine

Terminated

TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

Recurrent Glioblastoma

Australia, United States
EarliTec Diagnostics, Inc
Marcus Autism Center

Recruiting

Dynamic Quantification of Social-Visual Engagement in Autism Spectrum Disorder (ASD) For Children Ages 31-84 Months (MEASURE-ASD2)

Autism Spectrum Disorder | Autism

United States

3

Subscribe